January 1, 1986CirculationOpen Access

Short- and long-term therapy with tocainide for malignant ventricular tachyarrhythmias.

View Full Paper

Ask AI

Bookmark

Why the study?

Does tocainide reduce arrhythmias in patients with refractory recurrent ventricular tachyarrhythmias?

Population

228 patients with recurrent ventricular tachyarrhythmias refractory to therapy with conventional…

Design

Cohort

Follow-up

average 26.4 months for long-term cohort

Authors

SHS H HohnloserUniversity Medical Center Freiburg HLH. LangeMax Planck Society ERErnst A. RaederState University of New York

Discussion

Member takes

Implication

May support individualized tocainide use in refractory VT; leaves open prospective trials versus contemporary therapies.

Structured PICO

Does tocainide reduce arrhythmias in patients with refractory recurrent ventricular tachyarrhythmias?

Population

228 patients with recurrent ventricular tachyarrhythmias refractory to therapy with conventional antiarrhythmic drugs.

Intervention

Tocainide 1200 to 2400 mg/day for 4 days initially, followed by long-term treatment in 73 selected patients.

Outcome

Efficacy evaluated with monitoring and exercise testing or electrophysiologic testing; long-term incidence of sudden death and nonfatal recurrence of arrhythmia.hard clinical

Tocainide is an effective and well-tolerated long-term therapy for refractory malignant ventricular tachyarrhythmias when carefully evaluated and individualized.

Cite This Study

Hohnloser et al. (1986) studied this question.

synapsesocial.com/papers/6a70a141ac440176ef294bb2 https://doi.org/10.1161/01.cir.73.1.143

View Full Paper

Ask AI

Bookmark

Short- and long-term therapy with tocainide for malignant ventricular tachyarrhythmias.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Short- and long-term therapy with tocainide for malignant ventricular tachyarrhythmias.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider